ENTRY       D10821                      Drug
NAME        Emicizumab (USAN/INN);
            Emicizumab (genetical recombination) (JAN);
            Hemlibra (TN)
PRODUCT     HEMLIBRA (Genentech)
FORMULA     C2164H3334N572O690S18
EXACT_MASS  48949.8354
MOL_WEIGHT  48980.2152
SEQUENCE    (Heavy chain)
            QVQLVESGGG LVQPGGSLRL SCAASGFTFS YYDIQWVRQA PGKGLEWVSS ISPSGQSTYY
            RREVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRT GREYGGGWYF DYWGQGTLVT
            VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
            QSSGLYSLSS VVTVPSSSLG TQTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQYN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQKE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
            QEGNVFSCSV MHEALHNRYT QKSLSLSP
            (heavy chain)
            QVQLVQSGSE LKKPGASVKV SCKASGYTFT DNNMDWVRQA PGQGLEWMGD INTRSGGSIY
            NEEFQDRVIM TVDKSTDTAY MELSSLRSED TATYHCARRK SYGYYLDEWG EGTLVTVSSA
            STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQYNSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQEGN
            VFSCSVMHEA LHNHYTQESL SLSP
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCKASRNIE RQLAWYQQKP GQAPELLIYQ ASRKESGVPD
            RFSGSRYGTD FTLTISSLQP EDIATYYCQQ YSDPPLTFGG GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H137-L214, H150-H206, H229-h225, H232-h228, H264-H324, H370-H428, h22-h96, h133-L'214, h146-h202, h260-h320, h366-h424, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
REMARK      Therapeutic category: 6349
            ATC code: B02BX06
            Product: D10821<JP/US>
EFFICACY    Bleeding suppressant, Factor VIII replacement
  DISEASE   Hemophilia A [DS:H00219]
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Preventing bleeding in adults and children with hemophilia A
TARGET      F9 [HSA:2158] [KO:K01321]
            F10 [HSA:2159] [KO:K01314]
  PATHWAY   hsa04610(2158+2159)  Complement and coagulation cascades
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B02 ANTIHEMORRHAGICS
               B02B VITAMIN K AND OTHER HEMOSTATICS
                B02BX Other systemic hemostatics
                 B02BX06 Emicizumab
                  D10821  Emicizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Products and Modifiers
              Blood Component Deficiency/ Replacement
               Emicizumab
                D10821  Emicizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               634  Human blood preparations
                6349  Others
                 D10821  Emicizumab (USAN/INN); Emicizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                F10
                 D10821  Emicizumab (USAN/INN) &lt;JP/US&gt;
                F9
                 D10821  Emicizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10821
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10821
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10821
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10821
DBLINKS     CAS: 1610943-06-0
            PubChem: 319902621
///
